Sigyn Therapeutics annual ebitda
2020
2021
2023
Sigyn Therapeutics's calculated EBITDA was −$2.4M for fiscal 2023.
View full Sigyn Therapeutics company overview| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | −$2.4M | −$457,395 | — |
| 2021 | 2021-12-31 | −$2.0M | −$1.1M | — |
| 2020 | 2020-12-31 | −$905,134 | — | — |
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$715,626 | −$184,595 | — |
| Q2 2023 | 2023-09-30 | −$640,798 | −$110,622 | — |
| Q1 2023 | 2023-06-30 | −$571,394 | $35,238 | — |
| Q4 2022 | 2023-03-31 | −$518,643 | $69,731 | — |
| Q3 2022 | 2022-09-30 | −$531,031 | $41,000 | — |
| Q2 2022 | 2022-06-30 | −$530,176 | −$92,913 | — |
| Q1 2022 | 2022-03-31 | −$606,632 | −$215,234 | — |
| Q4 2021 | 2021-12-31 | −$588,374 | −$254,056 | — |
| Q3 2021 | 2021-09-30 | −$572,031 | −$369,414 | — |
| Q2 2021 | 2021-06-30 | −$437,263 | −$261,698 | — |
| Q1 2021 | 2021-03-31 | −$391,398 | −$198,764 | — |
| Q4 2020 | 2020-12-31 | −$334,318 | −$162,833 | — |
| Q3 2020 | 2020-09-30 | −$202,617 | $354,234 | — |
| Q2 2020 | 2020-06-30 | −$175,565 | — | — |
| Q1 2020 | 2020-03-31 | −$192,634 | — | — |
| Q2 2018 · Jun 30 | 2018-06-30 | −$171,485 | — | — |
| Q2 2018 · Jun 30 | 2017-06-30 | −$556,851 | — | — |
Across the available reported history, Sigyn Therapeutics's ebitda decreased from −$2.0M to −$2.4M, a change of −$457,395. The latest reported quarter, Q4 2023, shows −$715,626.
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics filings at SEC.gov ↗